Skip Ribbon Commands
Skip to main content

​​Cardiac Arrest Trial

A new ground breaking medical trial involving five ambulance services, including West Midlands Ambulance Service (WMAS), is due to begin on researching the effectiveness of the use of adrenaline in cases of cardiac arrest. The trial, called PARAMEDIC2, will primarily be run in the Black Country, Birmingham, Herefordshire and Worcestershire.

The trial funded by the National Institute for Health Research is being co-ordinated by the University of Warwick. There is an urgent need for a clinical trial to determine whether adrenaline therapy for cardiac arrest is safe and effective. The new study will determine if adrenaline is helpful as a treatment for cardiac arrest.

Gavin Perkins, Chief Investigator for the Trial explains:

Introduction

 

 
 

 

The International Liaison Committee on Resuscitation, European Resuscitation Council and Resuscitation Council (UK) which set the current resuscitation guidelines, have identified the urgent need for a clinical trial to determine whether  adrenaline therapy for cardiac arrest is safe and effective. The new study will work out once and for all if adrenaline is helpful or harmful as a treatment for cardiac arrest.

Method

 

 

A cardiac arrest is when the heart suddenly stops beating and the patient is unconscious. All people taking part in the study will receive standard treatments which are known to work (CPR and, if required defibrillation).  In addition, some people will receive adrenaline and some will not receive adrenaline.

Patients will be followed up in hospital and researchers will compare what happens and determine whether adrenaline works or not. The data will be analysed frequently as the trial progresses so that if a significant difference (one way or the other) is detected, the trial can be stopped early.

Speaking about the trial, Mike Smyth (pictured below), research fellow at Warwick Medical School and WMAS paramedic, said: “We’ve been using adrenaline in out-of-hospital cardiac arrest for over 50 years now, but we don’t know if it’s beneficial for improved patient outcomes. There has been data that had emerged recently that suggests patients who receive adrenaline during their resuscitation was worse neurologic (brain function) outcomes. Therefore it is important for us to find out for patients if we are harming them by giving them adrenaline.”

Reasons

 

 

The trial also involves four other ambulance Trusts (South Central Ambulance Service, London Ambulance Service, Welsh Ambulance Service and North East Ambulance Service) and commences in the West Midlands in June.

Reassurance

 

 

More information can be found on our social media sites by logging onto Facebook, Twitter, WordPress and YouTube.  Select the links to go to our officialwmas sites.

 

 

Logo for Paramedic2 Trial